Hodi FS, Pardoll DM, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J MedNat Rev Cancer. 20102012;363(8):711–23.

Pardoll, D.M., The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer, 2012. 12(4): p. 252 − 64.

Sharpe AH. Introduction to checkpoint inhibitors and cancer immunotherapy. Immunol Rev. 2017;276(1):5–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

McDermott DF, et al. Survival, durable response, and long-term safety in patients with previously treated Advanced Renal Cell Carcinoma receiving Nivolumab. J Clin Oncol. 2015;33(18):2013–20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wolchok JD, et al. Overall survival with combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2017;377(14):1345–56.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Eggermont AM, et al. Prolonged survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. N Engl J Med. 2016;375(19):1845–55.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Martins F, Kostine M, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin OncolAnn Rheum Dis. 20192018;16(9):563–80.

Kostine, M., et al., Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study. Ann Rheum Dis, 2018. 77(3): p. 393–398.

Richter MD, et al. Rheumatic syndromes Associated with Immune Checkpoint inhibitors: a single-center cohort of sixty-one patients. Arthritis Rheumatol. 2019;71(3):468–75.

Article  CAS  PubMed  Google Scholar 

Smolen JS, Aletaha D, McInnes IB. Rheumatoid Arthritis Lancet. 2016;388(10055):2023–38.

CAS  PubMed  Google Scholar 

McCarter KR, Sparks JA, et al. Immunomodulator use, risk factors and management of flares, and mortality for patients with pre-existing rheumatoid arthritis after immune checkpoint inhibitors for cancer. Semin Arthritis RheumRheum Dis Clin North Am. 20242024;64(2):p152335.

Sparks, J.A., Pre-existing Autoimmune Diseases and Immune Checkpoint Inhibitors for Cancer Treatment: Considerations About Initiation, Flares, Immune-Related Adverse Events, and Cancer Progression. Rheum Dis Clin North Am, 2024. 50(2): p. 147–159.

Chan KK, Bass AR. Monitoring and management of the patient with Immune Checkpoint inhibitor-Induced Inflammatory Arthritis: current perspectives. J Inflamm Res. 2022;15:3105–18.

Article  CAS  PubMed  PubMed Central  Google Scholar 

McCarter KR, et al. Mortality and immune-related adverse events after immune checkpoint inhibitor initiation for cancer among patients with pre-existing rheumatoid arthritis: a retrospective, comparative, cohort study. Lancet Rheumatol. 2023;5(5):e274–83.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brynjarsdottir HB, et al. Successful management of checkpoint inhibitor-Induced Arthritis with Disease-modifying antirheumatic drugs during active Immune Checkpoint Inhibition Treatment. J Rheumatol. 2023;50(9):1195–7.

Article  CAS  PubMed  Google Scholar 

Khoja L, et al. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol. 2017;28(10):2377–85.

Article  CAS  PubMed  Google Scholar 

Babamohamadi M, et al. Anti-CTLA-4 nanobody as a promising approach in cancer immunotherapy. Cell Death Dis. 2024;15(1):17.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee DJ, et al. Mechanisms driving Immune-related adverse events in Cancer patients treated with Immune Checkpoint inhibitors. Curr Cardiol Rep. 2021;23(8):98.

Article  PubMed  Google Scholar 

Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum. 1987;30(11):1205–13.

Article  CAS  PubMed  Google Scholar 

Klareskog L, et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum. 2006;54(1):38–46.

Article  CAS  PubMed  Google Scholar 

Cappelli LC, et al. Association of HLA-DRB1 shared epitope alleles and immune checkpoint inhibitor-induced inflammatory arthritis. Rheumatology (Oxford). 2019;58(3):476–80.

Article  CAS  PubMed  Google Scholar 

Ghosh N et al. Anticitrullinated peptide antibody epitope expansion and the HLA DRB1 ‘shared epitope’ are less common in seropositive checkpoint inhibitor-induced inflammatory arthritis than in longstanding rheumatoid arthritis. RMD Open, 2023. 9(2).

Wang R, et al. Clonally expanded CD38(hi) cytotoxic CD8 T cells define the T cell infiltrate in checkpoint inhibitor-associated arthritis. Sci Immunol. 2023;8(85):eadd1591.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim ST et al. Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nat Commun, 2022. 13(1): p. 1970.

Cappelli LC, et al. Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen. Semin Arthritis Rheum. 2018;48(3):553–7.

Article  PubMed  PubMed Central  Google Scholar 

Braaten TJ, et al. Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation. Ann Rheum Dis. 2020;79(3):332–8.

Article  CAS  PubMed  Google Scholar 

Zhou Z, et al. Single-cell profiling identifies IL1B(hi) macrophages associated with inflammation in PD-1 inhibitor-induced inflammatory arthritis. Nat Commun. 2024;15(1):2107.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ghosh N, et al. Checkpoint inhibitor-Associated Arthritis: a systematic review of Case reports and Case Series. J Clin Rheumatol. 2021;27(8):e317–22.

Article  PubMed  PubMed Central  Google Scholar 

Albayda J, et al. Sonographic findings in Inflammatory Arthritis secondary to Immune Checkpoint Inhibition: a Case Series. ACR Open Rheumatol. 2019;1(5):303–7.

Article  PubMed  PubMed Central  Google Scholar 

Liu Y, et al. Immune checkpoint inhibitor-induced inflammatory arthritis: a novel clinical entity with striking similarities to seronegative rheumatoid arthritis. Clin Rheumatol. 2020;39(12):3631–7.

Article  PubMed  Google Scholar 

Cappelli LC, et al. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis. 2017;76(1):43–50.

Article  CAS  PubMed  Google Scholar 

Calabrese C, et al. Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity. RMD Open. 2017;3(1):e000412.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mooradian MJ, et al. Musculoskeletal rheumatic complications of immune checkpoint inhibitor therapy: a single center experience. Semin Arthritis Rheum. 2019;48(6):1127–32.

Article  CAS  PubMed  Google Scholar 

Efuni E, et al. Risk of Toxicity after initiating Immune checkpoint inhibitor treatment in patients with rheumatoid arthritis. J Clin Rheumatol. 2021;27(7):267–71.

Article  PubMed  PubMed Central  Google Scholar 

Cappelli LC, Bingham CO 3. Expert Perspective: Immune Checkpoint inhibitors and rheumatologic complications. Arthritis Rheumatol. 2021;73(4):553–65.

Verheijden RJ, et al. Association of Anti-TNF with decreased survival in Steroid Refractory Ipilimumab and Anti-PD1-Treated patients in the Dutch Melanoma Treatment Registry. Clin Cancer Res. 2020;26(9):2268–74.

Article  CAS  PubMed  Google Scholar 

Salem JE, et al. Abatacept for severe Immune checkpoint inhibitor-Associated Myocarditis. N Engl J Med. 2019;380(24):2377–9.

Article  PubMed  Google Scholar 

Jespersen MS, et al. A case report of immune checkpoint inhibitor-related steroid-refractory myocarditis and myasthenia gravis-like myositis treated with abatacept and mycophenolate mofetil. Eur Heart J Case Rep. 2021;5(11):ytab342.

Article  PubMed  PubMed Central